Day & Ennis LLC Has $913,000 Position in Pfizer (PFE)

Day & Ennis LLC increased its position in Pfizer (NYSE:PFE) by 9.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,213 shares of the biopharmaceutical company’s stock after purchasing an additional 2,250 shares during the period. Day & Ennis LLC’s holdings in Pfizer were worth $913,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PFE. Mutual Advisors LLC purchased a new position in Pfizer in the 4th quarter worth about $1,036,000. Brown Advisory Securities LLC raised its position in Pfizer by 2.2% in the 4th quarter. Brown Advisory Securities LLC now owns 72,085 shares of the biopharmaceutical company’s stock worth $2,605,000 after buying an additional 1,556 shares during the last quarter. West Chester Capital Advisors Inc. purchased a new position in Pfizer in the 4th quarter worth about $470,000. State of Tennessee Treasury Department raised its position in Pfizer by 16.8% in the 4th quarter. State of Tennessee Treasury Department now owns 4,380,885 shares of the biopharmaceutical company’s stock worth $158,676,000 after buying an additional 629,141 shares during the last quarter. Finally, Pzena Investment Management LLC raised its position in Pfizer by 8.8% in the 4th quarter. Pzena Investment Management LLC now owns 4,361,143 shares of the biopharmaceutical company’s stock worth $157,961,000 after buying an additional 352,869 shares during the last quarter. Institutional investors own 71.65% of the company’s stock.

A number of equities analysts have weighed in on the company. Jefferies Group set a $38.00 target price on Pfizer and gave the stock a “hold” rating in a research report on Friday, April 13th. BMO Capital Markets decreased their target price on Pfizer from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday, May 2nd. Morgan Stanley upped their price target on shares of Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Citigroup reaffirmed a “sell” rating on shares of Pfizer in a research report on Thursday, April 12th. Finally, Morningstar set a $43.50 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, May 2nd. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $40.08.

In related news, CEO Ian C. Read sold 132,312 shares of the stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders sold a total of 380,349 shares of company stock valued at $13,829,340 over the last three months. 0.06% of the stock is currently owned by insiders.

Pfizer opened at $35.71 on Friday, MarketBeat Ratings reports. The company has a market capitalization of $212.46 billion, a P/E ratio of 13.48, a PEG ratio of 1.77 and a beta of 0.89. Pfizer has a 12-month low of $35.64 and a 12-month high of $35.80. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. The company had revenue of $12.91 billion during the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.69 EPS. analysts forecast that Pfizer will post 2.95 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio is 51.32%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply